Xingang  Cui

Prof. Xingang Cui


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
YHYi Huang
Yi Huang
XPXiu-Wu Pan
Xiu-Wu Pan
LLLin Li
Lin Li
LCLu Chen
Lu Chen
XLXi Liu
Xi Liu
XCXingang Cui
Xingang Cui
Overexpression of USP39 predicts poor prognosis and promotes tumorigenesis of prostate cancer via promoting EGFR mRNA maturation and transcription elongation

28 March 2016 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
XPXiu-Wu Pan
Xiu-Wu Pan
LCLu Chen
Lu Chen
YHYi Hong
Yi Hong
DXDan-Feng Xu
Dan-Feng Xu
XLXi Liu
Xi Liu
XCXingang Cui
Xingang Cui
There are no effective therapies for advanced renal cell carcinoma (RCC), except for VEGFR inhibitors with only ~50% response rate. To identify novel targets and biomarkers for RCC is of great importance in treating RCC. In this study, we observed that eukaryotic initiation factor 3d (EIF3D) expression was significantly increased in RCC compared with paracarcinoma tissue using immunohistochemistry staining and western blot analysis. Furthermore, bioinformatics meta-analysis using ONCOMINE microarray datasets showed that EIF3D mRNA expressions in CCRCC tissue specimens were significantly higher than that in normal tissue specimens. In addition, RCC tissue microarray demonstrated that elevated EIF3D expression was positively correlated with TNM stage and tumor size. EIF3D silencing in human 786-O and ACHN CCRCC cell lines by RNA interference demonstrated that EIF3D knockdown obviously inhibited cell proliferation and colony formation, caused G2/M arrest through downregulation of Cyclin B1 and Cdk1 and upregulation of p21, and induced apoptosis shown by sub-G1 accumulation and RARP cleavage. Moreover, correlation analysis using ONCOMINE microarray datasets indicated that increased EIF3D mRNA expression was positively correlated to PCNA, Cyclin B1 and CDK1 mRNA expression in RCC. Collectively, these results provide reasonable evidences that EIF3D may function as a potential proto-oncogene that participates in the occurrence and progression of RCC.

28 August 2017 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HHHai Huang
Hai Huang
QZQin Zhang
Qin Zhang
CYChen Ye
Chen Ye
JLJian-Min Lv
Jian-Min Lv
XLXi Liu
Xi Liu
WLWenhui Liu
Wenhui Liu

1 June 2015 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
XPXiuwu Pan
Xiuwu Pan
HHHai Huang
Hai Huang
YHYi Huang
Yi Huang
BLBing Liu
Bing Liu
XCXingang Cui
Xingang Cui
YHYi Hong
Yi Hong

18 September 2017 in Oncotarget
Verified
Journal Article
Open access
XLXi Liu
Xi Liu
LCLu Chen
Lu Chen
HHHai Huang
Hai Huang
JLJian-Min Lv
Jian-Min Lv
MCMing Chen
Ming Chen
XDXu Danfeng
Xu Danfeng
High expression of PDLIM5 facilitates cell tumorigenesis and migration by maintaining AMPK activation in prostate cancer High expression of PDLIM5 facilitates cell tumorigenesis and migration by maintaining AMPK activation in prostate cancer

27 November 2015 in BMC Urology
Verified
Journal Article
Open access
PDF file
YHYi Huang
Yi Huang
XPXiuwu Pan
Xiuwu Pan
QZQiwei Zhou
Qiwei Zhou
HHHai Huang
Hai Huang
LLLin Li
Lin Li
XCXingang Cui
Xingang Cui
Health-related quality-of-life (HRQoL) is an important consideration after radical cystectomy (RC). Lack of effective ways to assess HRQoL after RC and unawareness of disease-specific problems related to ileal conduit (IC) and orthotopic ileal neobladder (OIN) are serious problems. The present study was to evaluate and compare morbidity and HRQoL between IC and OIN after RC, and examine their unmet needs in the two groups. A retrospective analysis was made of 294 patients treated with RC in our hospital between 2007 and 2013. Matched pair analysis was used to determine the patients of IC and OIN groups. Patient HRQoL between IC and OIN groups was assessed using the bladder-specific bladder cancer index (BCI) and European Organization for Research and Treatment of Cancer Body Image scale (BIS) questionnaires. Unmet information of patients undergoing these two urinary diversions was recorded through individual interviews. Of the 117 included patients, 39 patients were treated with OIN and the other 78 matched patients with IC as controls for matched pair analysis. There was no significant difference in baseline characteristics between the two groups. OIN patients showed significantly better BIS scores in terms of HRQoL outcomes after RC at a short-term (1 year) follow-up level between the two groups. Interestingly, urinary bother (UB) and urinary function (UF) were poor in OIN patients at the one-year follow-up level, but there was no significant difference in UB between the two groups at the long term follow-up level. Unmet needs analysis showed that OIN patients had a more positive attitude towards treatment and participated in physical and social activities more positively, although they may have more urine leakage problems. The mean BIS score in OIN group patients was significantly better than that in IC group patients at the one-year follow-up level, but there was no significant difference at the long-term follow-up level. Due attention should be paid to some particular unmet needs in individual patients in managing the two UD modalities.